Multiple Myeloma Clinical Trials

NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex

MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...

NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6

EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM This is a randomized,...

NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1

(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...